Rachel McMinn - Mar 26, 2025 Form 4 Insider Report for Neurogene Inc. (NGNE)

Role: Chief Executive Officer, Director
Signature: /s/ Christine Mikail, as attorney-in-fact for Rachel McMinn
Stock symbol: NGNE
Transactions as of: Mar 26, 2025
Transactions value $: $0
Form type: 4
Date filed: 3/28/2025, 09:27 PM
Previous filing: Nov 25, 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NGNE	Common Stock	Award	$0	+23.9K	+1.91%	$0.00	1.27M	Mar 26, 2025	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NGNE	Employee Stock Option (Right to buy)	Award	$0	+144K		$0.00	144K	Mar 26, 2025	Common Stock	144K	$16.14	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Consist of 23,900 restricted stock units, which will vest in three equal annual installments beginning on the first anniversary of the grant date, subject to the Reporting Person's continued provision of services to the Issuer on each vesting date.
F2	This option represents the right to purchase 143,500 shares of the Issuer's common stock, one quarter of which will vest on the first anniversary of the grant date with the remaining three quarters vesting in equal monthly installments through the fourth anniversary of the grant date, subject to the Reporting Person's continued provision of service to the Issuer on each vesting date.